1. Home
  2. AKRO vs ORLA Comparison

AKRO vs ORLA Comparison

Compare AKRO & ORLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • ORLA
  • Stock Information
  • Founded
  • AKRO 2017
  • ORLA 2007
  • Country
  • AKRO United States
  • ORLA Canada
  • Employees
  • AKRO N/A
  • ORLA N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • ORLA Precious Metals
  • Sector
  • AKRO Health Care
  • ORLA Basic Materials
  • Exchange
  • AKRO Nasdaq
  • ORLA Nasdaq
  • Market Cap
  • AKRO 3.9B
  • ORLA 3.8B
  • IPO Year
  • AKRO 2019
  • ORLA N/A
  • Fundamental
  • Price
  • AKRO $50.56
  • ORLA $10.43
  • Analyst Decision
  • AKRO Strong Buy
  • ORLA Buy
  • Analyst Count
  • AKRO 6
  • ORLA 2
  • Target Price
  • AKRO $82.50
  • ORLA $14.50
  • AVG Volume (30 Days)
  • AKRO 1.1M
  • ORLA 1.3M
  • Earning Date
  • AKRO 08-08-2025
  • ORLA 08-11-2025
  • Dividend Yield
  • AKRO N/A
  • ORLA N/A
  • EPS Growth
  • AKRO N/A
  • ORLA N/A
  • EPS
  • AKRO N/A
  • ORLA 0.01
  • Revenue
  • AKRO N/A
  • ORLA $417,310,000.00
  • Revenue This Year
  • AKRO N/A
  • ORLA $158.56
  • Revenue Next Year
  • AKRO N/A
  • ORLA $13.13
  • P/E Ratio
  • AKRO N/A
  • ORLA $1,967.06
  • Revenue Growth
  • AKRO N/A
  • ORLA 67.06
  • 52 Week Low
  • AKRO $21.34
  • ORLA $3.24
  • 52 Week High
  • AKRO $58.40
  • ORLA $12.83
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 44.48
  • ORLA 45.38
  • Support Level
  • AKRO $50.60
  • ORLA $9.83
  • Resistance Level
  • AKRO $52.55
  • ORLA $12.83
  • Average True Range (ATR)
  • AKRO 1.83
  • ORLA 0.60
  • MACD
  • AKRO -0.35
  • ORLA -0.07
  • Stochastic Oscillator
  • AKRO 17.66
  • ORLA 19.98

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About ORLA Orla Mining Ltd.

Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.

Share on Social Networks: